Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$0.31
-5.8%
$0.45
$0.29
$2.39
$10.03M-1.26869,844 shs1.01 million shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.51
-8.1%
$2.64
$1.11
$10.54
$53.20M1.51324,064 shs349,630 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.61
-1.2%
$1.60
$1.03
$6.51
$50.23M-0.32441,793 shs151,199 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$1.09
+1.9%
$1.39
$0.85
$4.29
$48.91M0.95462,072 shs221,895 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-5.83%-24.37%-36.92%-25.61%-85.79%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-7.55%-13.89%+5.46%+55.42%-73.10%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-1.23%-10.06%+12.59%+3.87%-76.80%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
+1.87%-7.63%-14.17%-21.01%-69.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.592 of 5 stars
3.54.00.00.02.41.70.0
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
1.985 of 5 stars
3.51.00.00.02.01.70.6
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
1.9532 of 5 stars
3.45.00.00.00.00.00.6
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
1.4709 of 5 stars
3.73.00.00.00.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3.00
Buy$8.002,505.86% Upside
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
3.00
Buy$18.00617.13% Upside
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.75
Moderate Buy$4.00148.45% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
3.33
Buy$9.00725.69% Upside

Current Analyst Ratings Breakdown

Latest ACXP, ATNM, PDSB, and ANVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/24/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/11/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/9/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $12.00
5/15/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$8.00
5/15/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $17.00
5/12/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$0.03 per shareN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.67 per shareN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.51 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$14.10M-$0.70N/AN/AN/AN/A-526.78%-223.78%8/12/2025 (Estimated)
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.47N/AN/AN/AN/A-100.85%-47.89%N/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)

Latest ACXP, ATNM, PDSB, and ANVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.36N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.10N/AN/AN/AN/AN/A
8/12/2025Q2 2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.24N/AN/AN/AN/AN/A
5/14/2025Q1 2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.25-$0.21+$0.04-$0.21N/AN/A
5/13/2025Q1 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.47-$0.32+$0.15-$0.32N/AN/A
5/12/2025Q1 2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.14-$0.11+$0.03-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
1.93
1.93
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
10.68
10.68
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.29
2.33
2.33

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
26.00%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
6.00%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
9.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
330.76 million22.59 millionOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
319.49 million15.43 millionOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2045.71 million41.51 millionOptionable

Recent News About These Companies

The top headlines for PDS Health’s busy 2025 so far
ASIC consults on simplifying PDS guidance
PDS Health adds practices in 5 states
PDS arm inks pact to acquire 60% stake in GSC Link
PDS Biotechnology Corporation (PDSB) - Yahoo Finance
PDS Health ranked among most community-minded companies
Unpacking the PDS Phenomenon

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$0.31 -0.02 (-5.83%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.30 0.00 (-0.65%)
As of 08/1/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.51 -0.22 (-8.06%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$2.54 +0.03 (+1.24%)
As of 08/1/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.61 -0.02 (-1.23%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$1.09 +0.02 (+1.87%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.10 +0.01 (+0.92%)
As of 08/1/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.